no image
Featured

Iconic Raises $10M to Build Software That Understands the World’s Biggest Projects

<p>AMSTERDAM--(BUSINESS WIRE)--November 17, 2026--</p><p> Iconic has raised $10 million in seed funding led by Peak Capital, with participation from Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. </p><p> Since its founding in mid-2025, Iconic has signed five clients in energy, infrastructure, and AI infrastructure: a global energy major, a leading European utility, a major European airport, a European rail infrastructure owner, and a global contractor building semiconductor fabs and data centers. Each spends over $1 billion annually on capital projects. </p><p> An estimated $15 trillion is invested in capital projects annually, yet fewer than 3% are delivered on time, on budget, and to plan. Capital projects rarely fail because of engineering complexity, but because decisions are made without a complete understanding of the project. Information is fragmented across documents and systems shared by owners, contractors, and engineering firms. Decisions are hard to reverse, with consequences lasting years through delays, claims, and cost overruns. </p><p> “Software has always organized the documents, but it never understood the project. Capital projects fail in predictable ways, yet every new one is treated as unique, and what one team learns leaves with its people. We are building software that understands each project and remembers the ones before it,” said Krijn de Nood, Iconic's CEO and co-founder. </p><p> Iconic's proprietary AI software connects design, engineering, commercial, and contract information to identify contradictions, missing information, design flaws, and constraints before they cause rework or claims. In one review, Iconic found that the plot plan for a new industrial plant placed part of the facility inside the site's safety boundary, where construction was prohibited. Caught during design, it could be addressed before construction, avoiding redesign and months of delay. </p><p> “Iconic is becoming an important part in how we run tenders for our projects,” said Sander Tensen, Manager Engineering &amp; Technology at Eneco. “Most tenders we send out are now reviewed by Iconic first, whereby we always find things we need to improve. And our engineers spend less time cross-checking documents and more time on the engineering only they can do.” </p><p> Client demand is growing faster than Iconic’s team can serve it. The funding will expand its commercial and delivery teams in Amsterdam, support expansion into Germany, the UK, and the US, as well as extend the platform across the project lifecycle with blueprints for each project type, so every project improves the next. </p><p> “Capital projects are among the largest undertakings in the physical economy, yet far too few land on time, on budget, and on scope. The bottleneck is decision quality, not effort,” said Tea Elezi, Partner at Peak Capital. “Iconic is the shift behind our Blue Collar Renaissance thesis made real: AI-native software reaching the built world. With exceptional founders and blue-chip customers from day one, we are proud to lead this round.” </p><p> Iconic was founded by second-time founders Krijn de Nood and Richard Stronkman. Krijn led assurance reviews of megaprojects worth up to $15 billion at McKinsey before co-founding Meatable. Richard founded and exited PublicSonar, an AI company specializing in extracting early-warning signals from unstructured data, the same core capability that underpins Iconic. </p><p> <b>About Iconic</b> </p><p> Asset owners and contractors in energy, infrastructure, and AI use it to review documents, apply lessons learned and standards, and make better project decisions. Iconic is ISO 27001 certified, SOC 2 Type II compliant, and GDPR compliant. Founded in 2025 in Amsterdam, Iconic is backed by Peak Capital, Bridford Group, Common Magic, Graduate Ventures, NP-Hard, and Tiny VC. </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20261116725327r1&amp;sid=ventb&amp;distro=nx&amp;lang=en" style="width:0;height:0"><span class="bwct31415"></span></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="https://www.businesswire.com/news/home/20261116725327/en/" rel="nofollow">https://www.businesswire.com/news/home/20261116725327/en/</a></span></p><p> <b>Media contact <br></b>Megan McDonough <br><a rel="nofollow" href="mailto:megan@iconic.works" shape="rect">megan@iconic.works</a> </p>
no image

CompanAIn® Names Animal Health Veteran Brük Herbst Chief Operating Officer

<p><strong></strong></p><p class="bwalignc"><strong> <i>Former IDEXX, Covetrus and Zomedica executive to lead CompanAIn's next phase of growth</i> </strong></p><p></p><p>CHARLESTON, S.C.--(BUSINESS WIRE)--November 16, 2026--</p><p> CompanAIn<sup>®</sup>, an AI-native companion animal health platform building the longitudinal intelligence and connectivity layer for animal health, today announced the appointment of Brük Herbst as Chief Operating Officer. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20261116753217/en/" rel="nofollow">https://www.businesswire.com/news/home/20261116753217/en/</a></p><div id="bwbodyimg" style="width: 381px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20261116753217/en/2971411/4/Bruk_Herbst.jpg" alt="Brük Herbst, Chief Operating Officer, CompanAIn®. Animal health executive with more than 20 years of leadership experience across veterinary diagnostics, technology, and commercialization, Herbst will lead CompanAIn’s next phase of commercial growth and strategic partnerships."><p style="font-size:85%;">Brük Herbst, Chief Operating Officer, CompanAIn®. Animal health executive with more than 20 years of leadership experience across veterinary diagnostics, technology, and commercialization, Herbst will lead CompanAIn’s next phase of commercial growth and strategic partnerships.</p></div><p> Herbst brings more than two decades of leadership across veterinary diagnostics, laboratories, genomics, wearable technology, and AI. He previously served as Senior Vice President of the North America Commercial Organization at IDEXX, President of Global Diagnostics at Covetrus, Chief Commercial Officer at Zomedica, and President of Diagnostics and Commercial Strategy at Voyce. Most recently, he was CEO of Ellie Diagnostics and SeqCenter. </p><p> As COO, Herbst will guide CompanAIn's move from platform validation to commercial scale. He will drive adoption across veterinary organizations, expand partnerships with diagnostics companies, hospital groups and animal health technology providers, and lead commercialization of future platform capabilities. </p><p> "Brük will help us scale critical infrastructure for animal health," said Michelle Wiltse, founder and CEO of CompanAIn. "He understands both the value of diagnostics and data in veterinary medicine and where the gaps still exist. He brings the operating discipline, industry relationships and commercial experience to turn our vision into an ecosystem that works at scale." </p><p> "I've spent my career connecting what happens in the laboratory to what happens in the exam room," said Herbst. "The missing piece has always been context, particularly what happens at home between visits. CompanAIn is building the layer that brings those pieces together while keeping veterinarians firmly in control of clinical decisions." </p><p> The appointment follows CompanAIn's pre-seed raise from animal health industry leaders and the continued expansion of its expert advisory board. </p><p> <b>About CompanAIn</b> </p><p> CompanAIn is an AI-native companion animal health platform that connects fragmented information across the home, veterinary clinic and broader care ecosystem to create a continuously evolving view of each animal's health. Built around responsible AI and a veterinarian-centered care model, the platform supports canine, feline and equine health. </p><p> For more information, visit <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fcompanain.ai&amp;esheet=54641462&amp;newsitemid=20261116753217&amp;lan=en-US&amp;anchor=companain.ai&amp;index=1&amp;md5=c56cf5dab24a81ae11e44ad545c014f0" shape="rect">companain.ai</a>. </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20261116753217r1&amp;sid=ventb&amp;distro=nx&amp;lang=en" style="width:0;height:0"><span class="bwct31415"></span></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="https://www.businesswire.com/news/home/20261116753217/en/" rel="nofollow">https://www.businesswire.com/news/home/20261116753217/en/</a></span></p><p> <b>Media Contact: </b><br>Cindy Syracuse <br>Searchlight Marketing for CompanAIn <br><a rel="nofollow" href="mailto:Cindy@companain.ai" shape="rect">Cindy@companain.ai</a> </p>
no image

Rejoni Announces First Commercial Case Using the Juveena® Hydrogel System at CCRM Fertility of New Jersey

<p><strong></strong></p><p class="bwalignc"><strong> <i>Serena H. Chen, MD, performs first commercial procedure with newly FDA-approved Juveena, a bioabsorbable hydrogel designed to reduce adhesion reformation after hysteroscopic adhesiolysis</i> </strong></p><p></p><p>BURLINGTON, Mass.--(BUSINESS WIRE)--November 16, 2026--</p><p> Rejoni, Inc., a commercial-stage women's health company focused on uterine health, today announced that the first commercial procedure using the Juveena Hydrogel System has been performed by Serena H. Chen, MD, Founding Partner and Director of Advocacy, at CCRM Fertility of New Jersey in Livingston, N.J. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20261116137810/en/" rel="nofollow">https://www.businesswire.com/news/home/20261116137810/en/</a></p><p> Intrauterine adhesions (IUAs), the hallmark of Asherman's syndrome, form when the uterine lining is injured, most often after hysteroscopic surgery or uterine curettage. They may cause infertility, recurrent pregnancy loss, menstrual changes, and serious obstetric complications such as abnormal placentation. Surgical removal of adhesions (adhesiolysis) is the standard of care, but adhesions frequently re-form after surgery. In moderate-to-severe disease, published recurrence rates are high, and many patients need repeat procedures before they can try to conceive. </p><p> "Performing the first Juveena case was a meaningful moment for our team and for our patients," said Dr. Chen. "The Juveena hydrogel procedure was simple to complete at the end of the hysteroscopy and fit into our existing workflow. For women with intrauterine adhesions, the surgery is only half the battle. Adhesions that come back after adhesiolysis can mean more surgery, more delays, and lost time for patients who often do not have time to lose. Having an FDA-approved option backed by randomized controlled trial data is an important step toward reducing both how often adhesions recur and how severe they are when they do." </p><p> "Dr. Chen and the CCRM Fertility of New Jersey team are leaders in reproductive medicine, and we are proud that they performed the first commercial Juveena case," said John Nealon, President &amp; CEO at Rejoni. "Clinicians have told us that recurrent adhesions are one of the most frustrating problems in reproductive surgery. Our goal is to give surgeons a purpose-built, evidence-based tool that helps protect the result of their work." </p><p> <b>About Juveena</b> </p><p> The Juveena Hydrogel System is an FDA-approved, in situ-forming hydrogel system indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. The system uses a proprietary transcervical catheter to deliver two aqueous polymer solutions that rapidly form a soft, temporary hydrogel spacer. The hydrogel conforms to the uterine cavity and upper cervical canal, keeping the uterine walls apart while they heal. Juveena received FDA premarket approval in September 2026. </p><p> <b>Indication and Important Safety Information</b> </p><p> The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions. </p><p> The Juveena Hydrogel System should not be used in patients with hemorrhage, active pelvic infection, sexually transmitted disease, or pregnancy, or in patients with known hypersensitivity or allergy to polyethylene glycol (PEG) or FD&amp;C Blue #1 dye. Safety and effectiveness have not been established following hysteroscopic procedures other than adhesiolysis of moderate to severe intrauterine adhesions, or in patients undergoing thermal endometrial ablation. Patients should avoid pregnancy during the first complete menstrual cycle after treatment. Potential adverse reactions include discomfort, pain/cramping, infection, local inflammatory reaction, and allergic reaction. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician or licensed practitioner. For complete information, see the Instructions for Use at <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rejoni.com&amp;esheet=54641677&amp;newsitemid=20261116137810&amp;lan=en-US&amp;anchor=www.rejoni.com&amp;index=1&amp;md5=15b59f64bdd661e53cf97b8e77776e86" shape="rect">www.rejoni.com</a>. </p><p> <b>About Rejoni</b> </p><p> Rejoni, Inc. is a privately held, commercial-stage medical device company based in Burlington, Massachusetts, developing gynecologic products based on its proprietary biomaterials. Founded in June 2020, Rejoni is the latest venture from serial entrepreneur Amar Sawhney, who also founded Confluent Surgical, Ocular Therapeutix, and Augmenix. More information about Rejoni can be found at <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rejoni.com&amp;esheet=54641677&amp;newsitemid=20261116137810&amp;lan=en-US&amp;anchor=www.rejoni.com&amp;index=2&amp;md5=e6dc3dc39d2f4d0e633ea31fe855452f" shape="rect">www.rejoni.com</a>. </p><p> <b>About CCRM Fertility of New Jersey</b> </p><p> CCRM Fertility of New Jersey, formerly the Institute for Reproductive Medicine and Science (IRMS), is part of CCRM Fertility, a global pioneer in fertility treatment, research, and science. From its main center in Livingston, N.J., and offices throughout the state, CCRM Fertility of New Jersey provides IVF, fertility testing, fertility preservation, egg freezing, third-party reproduction, and reproductive surgery. Founded by Dr. William Schoolcraft in 1987, CCRM Fertility leverages its own data and a dedicated team of in-house reproductive endocrinologists, embryologists, and geneticists to deliver industry-leading outcomes. More information can be found at <a rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ccrmivf.com&amp;esheet=54641677&amp;newsitemid=20261116137810&amp;lan=en-US&amp;anchor=www.ccrmivf.com&amp;index=3&amp;md5=b3837a0ef20c85744e9ecb5e8263a04a" shape="rect">www.ccrmivf.com</a>. </p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20261116137810r1&amp;sid=ventb&amp;distro=nx&amp;lang=en" style="width:0;height:0"><span class="bwct31415"></span></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on businesswire.com: </span><span id="mmgallerylink-link"><a href="https://www.businesswire.com/news/home/20261116137810/en/" rel="nofollow">https://www.businesswire.com/news/home/20261116137810/en/</a></span></p><p> Nicole Shugrue <br>VP Market Development <br>Rejoni, Inc. <br><a rel="nofollow" href="mailto:Nicole.Shugrue@Rejoni.com" shape="rect">Nicole.Shugrue@Rejoni.com</a> </p><p> Jill Austin <br>Public Relations Manager <br>CCRM Fertility <br><a rel="nofollow" href="mailto:Jill.austin@unifiedhc.com" shape="rect">Jill.austin@unifiedhc.com</a> </p>
Subscribe to get latest news!

Deep insights for enterprise AI, data, and security leaders

By submitting your email, you agree to our Terms and Privacy Notice.

A cheerful horse trots through a computer screen in a stylized vector art.

Alibaba's AI video model rises to No. 2 in global rankings, as OpenAI's Sora and ByteDance's Seedance fall away

Alibaba Cloud on Sunday released HappyHorse 1.1, a major upgrade to its AI video generation model that the company says delivers production-ready video synthesis across core content creation scenarios. The model is now live on Alibaba Cloud Model Studio with full API access for enterprise customers and developers, accompanied by a 40% sitewide launch discount for the first two weeks.